Xeris Biopharma Holdings (XERS) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to 9.05%.
- Xeris Biopharma Holdings' EBIT Margin rose 328100.0% to 9.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.68%, marking a year-over-year increase of 277900.0%. This contributed to the annual value of 16.57% for FY2024, which is 102800.0% up from last year.
- According to the latest figures from Q3 2025, Xeris Biopharma Holdings' EBIT Margin is 9.05%, which was up 328100.0% from 6.27% recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' EBIT Margin ranged from a high of 9.05% in Q3 2025 and a low of 289.55% during Q2 2021
- In the last 5 years, Xeris Biopharma Holdings' EBIT Margin had a median value of 40.0% in 2023 and averaged 75.37%.
- In the last 5 years, Xeris Biopharma Holdings' EBIT Margin tumbled by -740800bps in 2021 and then soared by 2148000bps in 2022.
- Xeris Biopharma Holdings' EBIT Margin (Quarter) stood at 225.26% in 2021, then skyrocketed by 80bps to 45.77% in 2022, then skyrocketed by 52bps to 22.17% in 2023, then surged by 113bps to 2.79% in 2024, then skyrocketed by 224bps to 9.05% in 2025.
- Its last three reported values are 9.05% in Q3 2025, 6.27% for Q2 2025, and 5.14% during Q1 2025.